Associated Papers
Gene therapy targeting synaptopathy linked with Alzheimer's and Parkinson's disease.
Panda SP et al.
Neuroscience, 2026
G6PD deficiency triggers dopamine loss and the initiation of Parkinson's disease pathogenesis.
Stykel MG et al.
Cell Reports, 2025
Mechanism and Clinical Application Prospects of Mitochondrial DNA Single Nucleotide Polymorphism in Neurodegenerative Diseases.
Xu M et al.
Neurochemical Research, 2024
Consequences of variability in α-synuclein fibril structure on strain biology.
Holec SAM et al.
Acta Neuropathologica, 2022
Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions.
Castonguay AM et al.
Journal of Parkinson's Disease, 2021
Neuronal Soma-Derived Degradative Lysosomes Are Continuously Delivered to Distal Axons to Maintain Local Degradation Capacity.
Farfel-Becker T et al.
Cell Reports, 2019
Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein.
Yu WH et al.
Neurochemical Research, 2008
Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation.
Li W et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience, 2004
Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
Gomez-Isla T et al.
Neurobiology of Aging, 0
Select a paper to view details